Access Resources
The Michael J. Fox Foundation continually strives to communicate our scientific progress with the research community — through posters and presentations at meetings, in peer-reviewed scientific publications and with white paper reports.
-
-
The Michael J. Fox Foundation’s development and distribution of novel alpha-synuclein viral vectors to study Parkinson's disease.
-
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits
-
The Michael J. Fox Foundation’s Efforts to Understand the Relationship between GBA1 and Alpha-Synuclein through the Development and Characterization of Preclinical Models
-
The Michael J. Fox Foundation’s Efforts to Develop New Tools for Understanding LRRK2 Biology and the Role of LRRK2 in Parkinson’s Disease Pathology
-
Characterization of a humanized A53T alpha-synuclein (aSyn A53T KI) and alpha-synuclein KO (aSyn KO) models
-
The Michael J. Fox Foundation’s Strategy to Generate, Characterize, and Distribute Preclinical Antibody Tools for Investigating Rab Molecular Biology
Articles authored by Rachel Dolhun, MD, a movement disorder specialist on staff at MJFF, offer a practical review of topics related to Parkinson's disease for practicing clinicians.
No results were found.
Michael J. Fox Foundation publications supported through our OAP program.
We believe that the results of all MJFF-funded research should be promptly published and broadly disseminated to accelerate innovation and foster collaboration toward our shared goal of new treatments and cures for Parkinson’s disease.
Request open access coverage funds for your MJFF project here
-
Beta2-Adrenoreceptor Agonist Clenbuterol Produces Transient Decreases in Alpha-Synuclein mRNA but No Long-term Reduction in Protein
-
Analysis of hemisphere-dependent effects of unilateral intrastriatal injection of α-synuclein pre-formed fibrils on mitochondrial protein levels, dynamics, and function
-
-
The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models
-
Association of Motor and Nonmotor Symptoms With Health-Related Quality of Life in a Large Online Cohort of People With Parkinson Disease
-
Design of the PERSPECTIVE study: PERsonalized SPEeCh Therapy for actIVE conversation in Parkinson's disease (randomized controlled trial)
-
Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages
Breaking Research Updates
Read the latest developments in the field’s understanding and treatment of Parkinson’s disease.